Innovative Medicine
Backed by the Power of AI
BioXcel Therapeutics, Inc. is a
biopharmaceutical company developing transformative medicines in neuroscience utilizing artificial intelligence.
Innovative Medicine
Backed by the
Power of AI
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of AI
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D economics
- Shortens development timelines
- Increases probability of success
AI-Driven Transformative Medicines in Neuroscience
We utilize our unique and proprietary AI platform to identify, re-innovate, and develop potential new therapies
Apr 10, 2024
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaVIEW RELEASE
Mar 25, 2024
BioXcel Therapeutics Announces $25 Million Registered Direct OfferingVIEW RELEASE
Mar 15, 2024
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Apr 19, 2024 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
2.75
CHANGE
0.2 (7.84%)